Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Wednesday. Shares of…
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
New branded medicines are coming to market with ever-higher price tags as soon as the first day. Amgen Inc's (NASDAQ: AMGN) lung cancer treatment, Lumakras, carried a hefty price tag of $17,900 per patient monthly when it launched in 2021.
Chardan Capital Reiterates Buy on uniQure, Maintains $60 Price Target
Chardan Capital analyst Matthew Barcus reiterates uniQure (NASDAQ:QURE) with a Buy and maintains $60 price target.
UniQure In-Licenses Early-Stage Amyotrophic Lateral Sclerosis Candidate, Analyst Says Deal Compliments Its Pipeline
UniQure N.V. (NASDAQ: QURE) and Apic Bio entered into a global licensing agreement for APB-102 to treat superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
Newly Approved Drugs In US Command Over $200,000 On An Average
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.
Have A Look At William Blair’s Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Gainers
Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.
Goldman Sachs Maintains Buy on uniQure, Raises Price Target to $57
Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Buy and raises the price target from $47 to $57.
Goldman Sachs Maintains Buy on uniQure, Lowers Price Target to $48
Goldman Sachs analyst Julien Richer maintains uniQure (NASDAQ:QURE) with a Buy and lowers the price target from $54 to $48.